A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors

2010194 citationsJournal Article

Authors

Razelle Kurzrock · University of Colorado Denver

Amita Patnaik · University of Colorado Cancer Center

Joseph Aisner · University of Colorado Cancer Center

Terri Warren · University of Colorado Cancer Center

Stephen Leong · University of Colorado Cancer Center

Robert S. Benjamin · University of Colorado Denver

Sabine Eckhardt

Abstract

R1507 is well tolerated and shows antitumor activity in patients with solid neoplasms, in particular Ewing's sarcoma. The recommended dose for the weekly schedule is 9 mg/kg qW.

Topics & Keywords

Growth Hormone and Insulin-like Growth Factors Neuroendocrine Tumor Research Advances Metabolism, Diabetes, and Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 16, Issue 8, pp. 2458-2465

DOI: 10.1158/1078-0432.ccr-09-3220

Field-Weighted Citation Impact: 15.02